Sheena

Believes in positivity and the power of being positive. Loves to see the forest for the trees. Professional interests: MS, Immunology, Diabetes, Oncology

[Course5 Life Sciences @Course5_LifeSci]

Hot off the press!!! Potential practice changing EMBARK trial data in BCR prostate cancer patients $PFE Impressive MFS benefit with enza combo. Treatment intensification in early prostate cancer #AUA2023 #pfizer #janssen #bayer

[Course5 Life Sciences @Course5_LifeSci]

#ESMO22 is set to begin this week from Sep 9-13, 2022 in Paris, France. Check out Course5i curated list of key data readouts. See what promising new data will be presented in Prostate cancer.#clinicaltrials #lifesciences #oncology #pharma #healthcare #prostatecancer #esmo2022

[C5i @C5iai]

Proud Sponsor | We’re pleased to be at the industry’s gold standard, @PharmaCIConf. Meet us to know more about #Course5i’s AI solutions. https://t.co/pYK4962Prf
#Course5i #Course5ToTransformation #dataanalytics #AI #Course5AI #Course5AI #pharmaanalytics #pharma

[Course5 Life Sciences @Course5_LifeSci]

The #AANAM is set to begin next week. Check out #Course5i curated list of #MultipleSclerosis focused sessions @AANMember. #clinicaltrial #MS #neurology

[Course5 Life Sciences @Course5_LifeSci]

The ASCO GU 2022 is set to begin from next week. We look forward to attending highly interactive sessions based on the latest research advances in #prostatecancer. Here is Course5i curated list of Prostate cancer-focused sessions at this year's #GU22 #ClinicalResearch

[Course5 Life Sciences @Course5_LifeSci]

The ASCO GI 2022 is set to begin next week. We look forward to attending highly interactive sessions with multidisciplinary perspectives based on the latest research advances in #NETS. Here is Course5i curated list of NET-focused sessions at this year's #GI22 #pharmaceuticals

[Course5 Life Sciences @Course5_LifeSci]

The 3rd #GBMSummit is set to begin next week. The only industry led forum with common goal of accelerating clinical development of meaningful therapies for the treatment of #Glioblastoma (#GBM). Here is #Course5i curated list of GBM-focused sessions at #GBMSummit #pharmaceuticals

[Course5 Life Sciences @Course5_LifeSci]

PSMA PET for Castration-Resistant Prostate Cancer - How Far Have We Come? #EANM21 @officialEANM
Molecular imaging TNM classification for the whole-body staging of #prostatecancer

[Course5 Life Sciences @Course5_LifeSci]

Ongoing wave of #radioligand therapy in #prostate cancer has evolved #PSMA as an actionable target. Oncologists focus on changing #immunologically “cold” prostate cancer “hot” with combo/treatment synergies of PSMA directed therapy with PARPi/CPIADT/chemo #EANM21 @officialEANM

[Course5 Life Sciences @Course5_LifeSci]

Increasing use of #PSMA PET preoperatively in patients with intermediate and high-risk #prostatecancer, which is helpful in accessing regional lymph node metastases #EANM21 @officialEANM

[Course5 Life Sciences @Course5_LifeSci]

Smaller-scale #dosimetry is required to better estimate targeted #alpha therapy (TAT) radiotoxicity. Imaging is a challenge in #TAT #EANM21 @officialEANM

[Course5 Life Sciences @Course5_LifeSci]

Radioimmunotherapy for R/R B cell NHL: 3-year follow-up - 90Y-IT demonstrated #clinically meaningful anti-tumor activity in relapsed or refractory B cell #NHL, particularly notable for follicular #lymphoma (FL) and mucosa-associated #lymphoid tissue (MALT) #EANM21 @officialEANM

[Course5 Life Sciences @Course5_LifeSci]

131I-MIBG therapy with 666 MBq/kg followed by single high dose #chemotherapy and #HSCT is safe in pts with high-risk #neuroblastoma; warrant further studies to elucidate the long-term efficacy of the therapy protocol #EANM21 @officialEANM

[Course5 Life Sciences @Course5_LifeSci]

Patient-specific #dosimetric workflow based on a reduced number of #acquisitions and #alternative methods when #SPECT/CT planned acquisitions are missing. Lowest errors obtained for #STP-intra and STP-inter methods, with a late #acquisition (96H/144H) #EANM21 @officialEANM

[Course5 Life Sciences @Course5_LifeSci]

PRRT as #neoadjuvant therapy in #NET enabled surgery in 45% of patients with an intention of radical cure #EANM21 @officialEANM

[Course5 Life Sciences @Course5_LifeSci]

PSMA targeting therapy has the potential to deliver a high dose of radiation, precisely to the tumor site. PSMA is highly expressed in mCRPC #EANM21 @officialEANM

[Course5 Life Sciences @Course5_LifeSci]

#RAD-THYR Trial was stopped after interim analysis due to lack of response and severe toxicity. Experience with alpha emitters is limited and hasn’t shown any implemental clinical benefit but high toxicity #EANM2021

[Course5 Life Sciences @Course5_LifeSci]

We are attending #EANM21, the world-leading conference in the field of #nuclearmedicine. This year’s #EANM21 will provide insights on management and treatment of cancer with radiopharmaceuticals. Course5i is looking forward to learning the latest updates in #radiopharmaceuticals

[Course5 Life Sciences @Course5_LifeSci]

This is big development and gives some hope for #Ataxia patients. If approved it will be the first drug to be approved. @Friedreichsatax @ReataPharma #DrugAlert #clinicalresearch #FDA #RareDisease https://t.co/kLYt2esDbw

[Course5 Life Sciences @Course5_LifeSci]

#Ublituximab vs other anti-CD20s
#ECTRIMS2021 @ectrimscongress